The effect of acromegaly on thyroid disease
Long-term stimulation of thyroid follicular epithelium by high growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in patients with acromegaly can lead to thyroid dysfunction, goiter, thyroid nodules, and even thyroid cancer and thyroid-associated ophthalmopathy (TAO). Excessive GH/IGF-1 pr...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Japan Endocrine Society
2023-11-01
|
| Series: | Endocrine Journal |
| Subjects: | |
| Online Access: | https://www.jstage.jst.go.jp/article/endocrj/70/11/70_EJ23-0356/_html/-char/en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591690482843648 |
|---|---|
| author | Caiyan Mo Liyong Zhong |
| author_facet | Caiyan Mo Liyong Zhong |
| author_sort | Caiyan Mo |
| collection | DOAJ |
| description | Long-term stimulation of thyroid follicular epithelium by high growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in patients with acromegaly can lead to thyroid dysfunction, goiter, thyroid nodules, and even thyroid cancer and thyroid-associated ophthalmopathy (TAO). Excessive GH/IGF-1 promotes goiter and thyroid nodule formation, which can be reversed by normalizing the IGF-1 levels with surgery or medical treatment. Whether patients with acromegaly have an increased risk of thyroid cancer remains controversial, and routine thyroid ultrasonography and regular cancer screening are recommended in such cases, especially when the nodules possess malignant propensity. TAO is an autoimmune disease and newer treatments are being discovered against it. Recent studies have reported that the IGF-1 receptor (IGF-1R) plays an important role in the pathogenesis of TAO, and the IGF-1R inhibitor teprotumumab involves significantly improved disease endpoints in patients with active TAO. Thyroid-stimulating hormone (TSH) receptor (TSHR) and IGF-1R co-immunoprecipitate in orbital and thyroid tissues to form a functional complex; thus, combined therapy targeting TSHR and IGF-1R may be more effective than single therapy. |
| format | Article |
| id | doaj-art-3a5679f7cbf545d3b756e7eb43d0f3c7 |
| institution | Kabale University |
| issn | 1348-4540 |
| language | English |
| publishDate | 2023-11-01 |
| publisher | The Japan Endocrine Society |
| record_format | Article |
| series | Endocrine Journal |
| spelling | doaj-art-3a5679f7cbf545d3b756e7eb43d0f3c72025-01-22T06:23:18ZengThe Japan Endocrine SocietyEndocrine Journal1348-45402023-11-0170111051106010.1507/endocrj.EJ23-0356endocrjThe effect of acromegaly on thyroid diseaseCaiyan Mo0Liyong Zhong1Department of Endocrinology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, ChinaDepartment of Endocrinology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, ChinaLong-term stimulation of thyroid follicular epithelium by high growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in patients with acromegaly can lead to thyroid dysfunction, goiter, thyroid nodules, and even thyroid cancer and thyroid-associated ophthalmopathy (TAO). Excessive GH/IGF-1 promotes goiter and thyroid nodule formation, which can be reversed by normalizing the IGF-1 levels with surgery or medical treatment. Whether patients with acromegaly have an increased risk of thyroid cancer remains controversial, and routine thyroid ultrasonography and regular cancer screening are recommended in such cases, especially when the nodules possess malignant propensity. TAO is an autoimmune disease and newer treatments are being discovered against it. Recent studies have reported that the IGF-1 receptor (IGF-1R) plays an important role in the pathogenesis of TAO, and the IGF-1R inhibitor teprotumumab involves significantly improved disease endpoints in patients with active TAO. Thyroid-stimulating hormone (TSH) receptor (TSHR) and IGF-1R co-immunoprecipitate in orbital and thyroid tissues to form a functional complex; thus, combined therapy targeting TSHR and IGF-1R may be more effective than single therapy.https://www.jstage.jst.go.jp/article/endocrj/70/11/70_EJ23-0356/_html/-char/enacromegalygrowth hormone (gh)insulin-like growth factor-1 (igf-1)thyroid |
| spellingShingle | Caiyan Mo Liyong Zhong The effect of acromegaly on thyroid disease Endocrine Journal acromegaly growth hormone (gh) insulin-like growth factor-1 (igf-1) thyroid |
| title | The effect of acromegaly on thyroid disease |
| title_full | The effect of acromegaly on thyroid disease |
| title_fullStr | The effect of acromegaly on thyroid disease |
| title_full_unstemmed | The effect of acromegaly on thyroid disease |
| title_short | The effect of acromegaly on thyroid disease |
| title_sort | effect of acromegaly on thyroid disease |
| topic | acromegaly growth hormone (gh) insulin-like growth factor-1 (igf-1) thyroid |
| url | https://www.jstage.jst.go.jp/article/endocrj/70/11/70_EJ23-0356/_html/-char/en |
| work_keys_str_mv | AT caiyanmo theeffectofacromegalyonthyroiddisease AT liyongzhong theeffectofacromegalyonthyroiddisease AT caiyanmo effectofacromegalyonthyroiddisease AT liyongzhong effectofacromegalyonthyroiddisease |